Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Season 2 - Ep. 3: Arrhythmogenic mitral valve prolapse - Peripartum cardiomyopathy

Season 2 - Ep. 3: Arrhythmogenic mitral valve prolapse - Peripartum cardiomyopathy

FromESC TV Today – Your Cardiovascular News


Season 2 - Ep. 3: Arrhythmogenic mitral valve prolapse - Peripartum cardiomyopathy

FromESC TV Today – Your Cardiovascular News

ratings:
Length:
21 minutes
Released:
Oct 26, 2023
Format:
Podcast episode

Description

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Peripartum cardiomyopathy Arrhythmogenic mitral valve prolapse Statistics Made Easy: The ‘Win Ratio’ Host: Perry Elliott Guests: Carlos Aguiar, Johann Bauersachs and Kristina Haugaa Want to watch that episode? Go to: https://esc365.escardio.org/event/1138 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Kristina Haugaa and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Johann Bauersachs has declared to have potential conflicts of interest to report: direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. by Roche Diagnostics (Acute Heart Failure), Pfizer (Atrial Fibrillation), Bristol Myers Squibb (Atrial Fibrillation), Bayer (Chronic Heart Failure), Boehringer-Ingelheim (Chronic Heart Failure), Novartis (Chronic Heart Failure), CVRx (Chronic Heart Failure), AstraZeneca (Chronic Heart Failure), Cardior (Chronic Heart Failure), Norgine (Chronic Heart Failure). Research funding from healthcare industry under your direct/personal responsibility (to department or institution): Roche Diagnostics (Atrial fibrillation, co-investigator), Norgine (heart failure / iron deficiency, principal investigator), Zoll Medical (heart failure, co-investigator), CVRx (heart failure, investigator). Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics.  Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.
Released:
Oct 26, 2023
Format:
Podcast episode

Titles in the series (38)

The European Society of Cardiology brings you the most relevant news in cardiovascular medicine, opinions from leading experts, and insight into the latest developments in our field that really matter. You can also be interested in other ESC podcasts: ESC Cardio Talk, EHRA Cardio Talk and HFA Cardio Talk. Check them out!